{"transactions":[{"id":915819,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T16:06:23.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":114000,"source":{"system":"sec-edgar","filing":"0001193125-26-041167","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000119312526041167/ownership.xml","form_type":"4"}},{"id":1278485,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T16:32:17.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0000950170-25-016346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000095017025016346/ownership.xml","form_type":"4"}},{"id":1309868,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T19:30:33.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025."}],"balance_after":25000,"derivative":{"exercise_price":14,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-000929","document":"form4-01062025_070130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000141588925000929/form4-01062025_070130.xml","form_type":"4"}},{"id":1309867,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-01-06T19:30:33.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."}],"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001415889-25-000929","document":"form4-01062025_070130.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000141588925000929/form4-01062025_070130.xml","form_type":"4"}},{"id":1651299,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T16:04:00.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001562180-24-001214","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218024001214/primarydocument.xml","form_type":"4"}},{"id":1687179,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T18:35:31.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024."}],"balance_after":24000,"derivative":{"exercise_price":18.08,"expiration_date":"2034-01-02","underlying":"Ordinary Shares","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-24-000889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919124000889/doc4.xml","form_type":"4"}},{"id":1687178,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-01-04T18:35:31.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."}],"balance_after":33500,"source":{"system":"sec-edgar","filing":"0001209191-24-000889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919124000889/doc4.xml","form_type":"4"}},{"id":2032341,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T16:54:02.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0001562180-23-000944","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000944/primarydocument.xml","form_type":"4"}},{"id":2054539,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-13","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.58,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054538,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-13","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.58,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054537,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-12","kind":"exercise","acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.47,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054536,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-13","kind":"sale","acquired":false,"shares":5000,"price":27,"value":135000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054535,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-13","kind":"exercise","acquired":true,"shares":5000,"price":13.58,"value":67900.0,"ownership":{"direct":true},"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054534,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-13","kind":"sale","acquired":false,"shares":10000,"price":27,"value":270000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054533,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-13","kind":"exercise","acquired":true,"shares":10000,"price":13.58,"value":135800.0,"ownership":{"direct":true},"balance_after":42000,"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054532,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-12","kind":"sale","acquired":false,"shares":24000,"price":26.7409,"value":641781.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $26.50 to $26.93."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2054531,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-13T16:44:07.000Z","date":"2023-01-12","kind":"exercise","acquired":true,"shares":24000,"price":9.47,"value":227280.0,"ownership":{"direct":true},"balance_after":56000,"source":{"system":"sec-edgar","filing":"0001562180-23-000413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218023000413/primarydocument.xml","form_type":"4"}},{"id":2061870,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:05:54.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023."}],"balance_after":23000,"derivative":{"exercise_price":29.6,"expiration_date":"2033-01-03","underlying":"Ordinary Shares","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-23-002176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919123002176/doc4.xml","form_type":"4"}},{"id":2061869,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-01-05T21:05:54.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."}],"balance_after":21500,"source":{"system":"sec-edgar","filing":"0001209191-23-002176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919123002176/doc4.xml","form_type":"4"}},{"id":2190546,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-08-09T16:05:04.000Z","date":"2022-08-05","kind":"exercise","acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.93,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001562180-22-005979","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022005979/primarydocument.xml","form_type":"4"}},{"id":2190545,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-08-09T16:05:04.000Z","date":"2022-08-05","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.63,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-22-005979","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022005979/primarydocument.xml","form_type":"4"}},{"id":2190544,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T16:05:04.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":14000,"price":23.0159,"value":322222.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $23.00 to $23.12"}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-005979","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022005979/primarydocument.xml","form_type":"4"}},{"id":2190543,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T16:05:04.000Z","date":"2022-08-05","kind":"exercise","acquired":true,"shares":14000,"price":8.93,"value":125020.0,"ownership":{"direct":true},"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001562180-22-005979","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022005979/primarydocument.xml","form_type":"4"}},{"id":2190542,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T16:05:04.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":10000,"price":23.0159,"value":230159.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $23.00 to $23.12"}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-005979","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022005979/primarydocument.xml","form_type":"4"}},{"id":2190541,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T16:05:04.000Z","date":"2022-08-05","kind":"exercise","acquired":true,"shares":10000,"price":9.63,"value":96300.0,"ownership":{"direct":true},"balance_after":42000,"source":{"system":"sec-edgar","filing":"0001562180-22-005979","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022005979/primarydocument.xml","form_type":"4"}},{"id":2413115,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T17:30:19.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-001073","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218022001073/primarydocument.xml","form_type":"4"}},{"id":2442985,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T17:24:34.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":20000,"derivative":{"exercise_price":60.87,"expiration_date":"2032-01-03","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-001821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919122001821/doc4.xml","form_type":"4"}},{"id":2442984,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-01-05T17:24:34.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs are fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-22-001821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919122001821/doc4.xml","form_type":"4"}},{"id":2460610,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":97860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.331495 to GBP 1.00 as of December 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":23312,"derivative":{"exercise_price":8.48,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":97860},"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460609,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-21","kind":"exercise","acquired":false,"shares":44537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.324735 to GBP 1.00 as of December 21, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":121172,"derivative":{"exercise_price":8.44,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":44537},"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460608,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":7603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.319915 to GBP 1.00 as of December 20, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":165709,"derivative":{"exercise_price":8.41,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":7603},"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460607,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":97860,"price":58.01,"value":5676858.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.50 inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460606,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":97860,"price":8.48,"value":829852.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.331495 to GBP 1.00 as of December 22, 2021."}],"balance_after":97860,"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460605,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-21","kind":"sale","acquired":false,"shares":44537,"price":57.11,"value":2543508.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.02 to $57.55 inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460604,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-21","kind":"exercise","acquired":true,"shares":44537,"price":8.44,"value":375892.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.324735 to GBP 1.00 as of December 21, 2021."}],"balance_after":44537,"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460603,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":7603,"price":57.02,"value":433523.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (7)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460602,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-22T21:00:20.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":7603,"price":8.41,"value":63941.23,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.319915 to GBP 1.00 as of December 20, 2021."}],"balance_after":7603,"source":{"system":"sec-edgar","filing":"0001209191-21-071007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121071007/doc4.xml","form_type":"4"}},{"id":2460601,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-22T18:25:16.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-21-007866","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021007866/primarydocument.xml","form_type":"4"}},{"id":2460600,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-22T18:25:16.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.08,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-21-007866","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021007866/primarydocument.xml","form_type":"4"}},{"id":2460599,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T18:25:16.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":24000,"price":22.0086,"value":528206.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $22.00 to $22.02."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001562180-21-007866","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021007866/primarydocument.xml","form_type":"4"}},{"id":2460598,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T18:25:16.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":24000,"price":7.88,"value":189120.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001562180-21-007866","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021007866/primarydocument.xml","form_type":"4"}},{"id":2460597,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T18:25:16.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":20000,"price":21.0125,"value":420250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $21.00 to $21.0238."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001562180-21-007866","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021007866/primarydocument.xml","form_type":"4"}},{"id":2460596,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T18:25:16.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":20000,"price":7.08,"value":141600.0,"ownership":{"direct":true},"balance_after":36000,"source":{"system":"sec-edgar","filing":"0001562180-21-007866","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021007866/primarydocument.xml","form_type":"4"}},{"id":2751943,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-09T16:36:31.000Z","date":"2021-04-08","kind":"exercise","acquired":false,"shares":24838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":173312,"derivative":{"exercise_price":8.74,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":24838},"source":{"system":"sec-edgar","filing":"0001209191-21-026247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121026247/doc4.xml","form_type":"4"}},{"id":2751942,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-09T16:36:31.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":239,"price":32.13,"value":7679.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $32.16 inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-026247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121026247/doc4.xml","form_type":"4"}},{"id":2751941,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-09T16:36:31.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":12099,"price":31.4,"value":379908.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to\n$31.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4)."}],"balance_after":239,"source":{"system":"sec-edgar","filing":"0001209191-21-026247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121026247/doc4.xml","form_type":"4"}},{"id":2751940,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-09T16:36:31.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":12500,"price":32,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."}],"balance_after":12338,"source":{"system":"sec-edgar","filing":"0001209191-21-026247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121026247/doc4.xml","form_type":"4"}},{"id":2751939,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-09T16:36:31.000Z","date":"2021-04-08","kind":"exercise","acquired":true,"shares":24838,"price":8.74,"value":217084.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.37265 to GBP 1.00 as of April 8, 2021."}],"balance_after":24838,"source":{"system":"sec-edgar","filing":"0001209191-21-026247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121026247/doc4.xml","form_type":"4"}},{"id":2753945,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-07T19:22:00.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.38618 to GBP 1.00 as of April 5, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":198150,"derivative":{"exercise_price":8.83,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":162},"source":{"system":"sec-edgar","filing":"0001209191-21-025990","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121025990/doc4.xml","form_type":"4"}},{"id":2753944,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-07T19:22:00.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":162,"price":31.07,"value":5033.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-025990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121025990/doc4.xml","form_type":"4"}},{"id":2753943,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-07T19:22:00.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":162,"price":8.83,"value":1430.46,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.38618 to GBP 1.00 as of April 5, 2021."}],"balance_after":162,"source":{"system":"sec-edgar","filing":"0001209191-21-025990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121025990/doc4.xml","form_type":"4"}},{"id":2760561,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-02T16:44:40.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.37827 to GBP 1.00 as of March 31, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":198312,"derivative":{"exercise_price":8.78,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-024639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121024639/doc4.xml","form_type":"4"}},{"id":2760560,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-02T16:44:40.000Z","date":"2021-03-31","kind":"sale","acquired":false,"shares":10000,"price":30,"value":300000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-024639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121024639/doc4.xml","form_type":"4"}},{"id":2760559,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-02T16:44:40.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":10000,"price":8.78,"value":87800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.37827 to GBP 1.00 as of March 31, 2021."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-21-024639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121024639/doc4.xml","form_type":"4"}},{"id":2766032,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:39.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":9.38,"expiration_date":"2030-07-21","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-014108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924321014108/doc4.xml","form_type":"4"}},{"id":2766031,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:39.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":8.78,"expiration_date":"2029-07-09","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-014108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924321014108/doc4.xml","form_type":"4"}},{"id":2766030,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:39.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":36650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":8.01,"expiration_date":"2028-11-21","underlying":"Common Shares","underlying_shares":36650},"source":{"system":"sec-edgar","filing":"0000899243-21-014108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924321014108/doc4.xml","form_type":"4"}},{"id":2766029,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:39.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":13350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":7.53,"expiration_date":"2028-06-09","underlying":"Common Shares","underlying_shares":13350},"source":{"system":"sec-edgar","filing":"0000899243-21-014108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924321014108/doc4.xml","form_type":"4"}},{"id":2766028,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-31T12:30:39.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Immediately prior to the consummation of the Merger, these securities were time-based restricted share units (\"RSUs\") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan.  Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924321014108/doc4.xml","form_type":"4"}},{"id":2766027,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-31T12:30:39.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":12480,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924321014108/doc4.xml","form_type":"4"}},{"id":2777308,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T16:48:26.000Z","date":"2021-03-17","kind":"exercise","acquired":false,"shares":7784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3898 to GBP 1.00 as of March 17, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":208312,"derivative":{"exercise_price":8.85,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":7784},"source":{"system":"sec-edgar","filing":"0001209191-21-022103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121022103/doc4.xml","form_type":"4"}},{"id":2777307,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-03-19T16:48:26.000Z","date":"2021-03-17","kind":"sale","acquired":false,"shares":7784,"price":29,"value":225736.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-022103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121022103/doc4.xml","form_type":"4"}},{"id":2777306,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-03-19T16:48:26.000Z","date":"2021-03-17","kind":"exercise","acquired":true,"shares":7784,"price":8.85,"value":68888.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3898 to GBP 1.00 as of March 17, 2021."}],"balance_after":7784,"source":{"system":"sec-edgar","filing":"0001209191-21-022103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121022103/doc4.xml","form_type":"4"}},{"id":2785617,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-16T19:42:18.000Z","date":"2021-03-12","kind":"exercise","acquired":false,"shares":2216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39126 to GBP 1.00 as of March 12, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022."}],"balance_after":216096,"derivative":{"exercise_price":8.86,"expiration_date":"2029-04-25","underlying":"Ordinary Shares","underlying_shares":2216},"source":{"system":"sec-edgar","filing":"0001209191-21-021154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121021154/doc4.xml","form_type":"4"}},{"id":2785616,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-03-16T19:42:18.000Z","date":"2021-03-12","kind":"sale","acquired":false,"shares":2216,"price":29,"value":64264.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-021154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121021154/doc4.xml","form_type":"4"}},{"id":2785615,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-03-16T19:42:18.000Z","date":"2021-03-12","kind":"exercise","acquired":true,"shares":2216,"price":8.86,"value":19633.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39126 to GBP 1.00 as of March 12, 2021."}],"balance_after":2216,"source":{"system":"sec-edgar","filing":"0001209191-21-021154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121021154/doc4.xml","form_type":"4"}},{"id":2876377,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-05T16:18:18.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant.  The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001562180-21-000928","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218021000928/primarydocument.xml","form_type":"4"}},{"id":2919229,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T17:44:20.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38000,"derivative":{"exercise_price":17.95,"exercise_date":"2021-01-04","expiration_date":"2031-01-04","underlying":"Ordinary Shares","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001209191-21-001407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919121001407/doc4.xml","form_type":"4"}},{"id":3076778,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-23T16:33:17.000Z","date":"2020-07-21","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option shall vest and become exercisable on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":9.38,"expiration_date":"2030-07-21","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-043484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919120043484/doc4.xml","form_type":"4"}},{"id":3076777,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-23T16:33:17.000Z","date":"2020-07-21","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units shall vest on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date."}],"balance_after":21480,"source":{"system":"sec-edgar","filing":"0001209191-20-043484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919120043484/doc4.xml","form_type":"4"}},{"id":3168913,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-27T16:49:28.000Z","date":"2019-06-28","kind":"grant","acquired":true,"shares":116827,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates."}],"balance_after":116827,"derivative":{"exercise_price":14,"expiration_date":"2029-06-28","underlying":"Ordinary Shares","underlying_shares":116827},"source":{"system":"sec-edgar","filing":"0001209191-20-025817","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919120025817/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-30"}},{"id":3270010,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T16:35:18.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24000,"derivative":{"exercise_price":9.47,"exercise_date":"2021-02-12","expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-20-001230","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218020001230/primarydocument.xml","form_type":"4"}},{"id":3311422,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-01-14T16:06:29.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":12480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units shall vest on January 10, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date."}],"balance_after":12480,"source":{"system":"sec-edgar","filing":"0001209191-20-003283","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919120003283/doc4.xml","form_type":"4"}},{"id":3317605,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-06T17:16:02.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32000,"derivative":{"exercise_price":9.82,"exercise_date":"2020-01-02","expiration_date":"2030-01-02","underlying":"Ordinary Shares","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-20-002019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919120002019/doc4.xml","form_type":"4"}},{"id":3463419,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-11T13:15:12.000Z","date":"2019-07-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":8.78,"expiration_date":"2029-07-09","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-041790","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000120919119041790/doc4.xml","form_type":"4"}},{"id":3492373,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-12T09:00:43.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24000,"derivative":{"exercise_price":7.88,"exercise_date":"2020-06-10","expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-19-003490","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218019003490/primarydocument.xml","form_type":"4"}},{"id":3507219,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-30T21:25:40.000Z","date":"2019-05-28","kind":"grant","acquired":true,"shares":116827,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant."}],"balance_after":116827,"derivative":{"exercise_price":14,"expiration_date":"2029-05-28","underlying":"Ordinary Shares","underlying_shares":116827},"source":{"system":"sec-edgar","filing":"0001104659-19-032913","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000110465919032913/a4.xml","form_type":"4"}},{"id":3752732,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-26T20:38:35.000Z","date":"2018-11-21","kind":"grant","acquired":true,"shares":36650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on November 9, 2019, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":36650,"derivative":{"exercise_price":8.01,"expiration_date":"2028-11-21","underlying":"Common Shares","underlying_shares":36650},"source":{"system":"sec-edgar","filing":"0000899243-18-029669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000089924318029669/doc4.xml","form_type":"4"}},{"id":3885173,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-22T17:15:38.000Z","date":"2018-06-22","kind":"disposition_to_issuer","acquired":false,"shares":55765,"price":43.2657,"value":2412711.7605,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Bluegill Acquisition Corporation (\"Merger Sub\"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the \"Offer\") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the \"Offer Price\"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which provided for vesting in forty-eight equal monthly installments following April 18, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":6.7343,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":55765},"source":{"system":"sec-edgar","filing":"0000899243-18-017720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318017720/doc4.xml","form_type":"4"}},{"id":3885172,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-22T17:15:38.000Z","date":"2018-06-22","kind":"disposition_to_issuer","acquired":false,"shares":18000,"price":10.03,"value":180540.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Bluegill Acquisition Corporation (\"Merger Sub\"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the \"Offer\") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the \"Offer Price\"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":39.97,"expiration_date":"2028-03-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-18-017720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318017720/doc4.xml","form_type":"4"}},{"id":3916742,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-25T08:59:58.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14000,"derivative":{"exercise_price":8.93,"exercise_date":"2019-05-23","expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001562180-18-002681","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218018002681/primarydocument.xml","form_type":"4"}},{"id":3980956,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-28T16:56:15.000Z","date":"2018-03-26","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares of common stock subject to the option vest on the last day of the calendar month in which the option was granted, and 1/36th of the shares subject to the option vest on the last day of the 35 calendar months immediately thereafter."}],"balance_after":18000,"derivative":{"exercise_price":39.97,"expiration_date":"2028-03-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-18-008732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318008732/doc4.xml","form_type":"4"}},{"id":4065673,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T16:01:08.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":10000,"derivative":{"exercise_price":9.63,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-18-000722","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218018000722/primarydocument.xml","form_type":"4"}},{"id":4311416,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-19T11:26:50.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":5000,"derivative":{"exercise_price":13.58,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-002008","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218017002008/primarydocument.xml","form_type":"4"}},{"id":4311415,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-19T11:26:50.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"derivative":{"exercise_price":13.58,"exercise_date":"2018-05-17","expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-17-002008","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218017002008/primarydocument.xml","form_type":"4"}},{"id":4497776,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-05T17:05:46.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":20000,"derivative":{"exercise_price":7.08,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-17-000193","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1391045/000156218017000193/primarydocument.xml","form_type":"4"}},{"id":4567445,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:30:24.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":17695,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2025-01-01","underlying":"Common Stock","underlying_shares":17695},"source":{"system":"sec-edgar","filing":"0001209191-16-148106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148106/doc4.xml","form_type":"4"}},{"id":4567444,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:30:24.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":17778,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.91,"expiration_date":"2026-01-12","underlying":"Common Stock","underlying_shares":17778},"source":{"system":"sec-edgar","filing":"0001209191-16-148106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148106/doc4.xml","form_type":"4"}},{"id":4567443,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:30:24.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16.52,"expiration_date":"2025-07-08","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-16-148106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148106/doc4.xml","form_type":"4"}},{"id":4567442,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:30:24.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":535,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":42.93,"expiration_date":"2023-12-31","underlying":"Common Stock","underlying_shares":535},"source":{"system":"sec-edgar","filing":"0001209191-16-148106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148106/doc4.xml","form_type":"4"}},{"id":4567441,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67394,"kind":"person","name":"Legault Pierre","position":1,"cik":"0001391045","reported_name":"Legault Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:30:24.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":6111,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":43.83,"expiration_date":"2023-11-17","underlying":"Common Stock","underlying_shares":6111},"source":{"system":"sec-edgar","filing":"0001209191-16-148106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148106/doc4.xml","form_type":"4"}}]}